PRQR
NASDAQProQR Therapeutics N.V.
ProQR Therapeutics N.V. (PRQR) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 2 wire items for PRQR, including 2 SEC filings. The most recent was published Oct 30, 2026.
PRQR rankings
Financial highlights
Full financials- Revenue, FY2025
- €15.91M
- Revenue growth
- -15.9%
- Net income, FY2025
- -€42.18M
- Net margin
- -265.2%
- Free cash flow, FY2025
- -€53.81M
- Cash
- €92.41M
For fiscal 2025 (ended Dec 31, 2025), from SEC filings. Not investment advice.
News · 26 weeks300%
2026-05-172026-11-08
Mix1190d
- SEC Filings6(55%)
- Other2(18%)
- Offering1(9%)
- Analyst1(9%)
- Leadership1(9%)
Activity · 52 weeks6635 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- SECAmendment: SEC Form 6-K/A filed by ProQR Therapeutics N.V.6-K/A - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI AdvisorAppointments support ProQR’s strategy to scale AI across the discovery and development of medicines using its Axiomer RNA editing platform and pipelineAX-0811, the first ProQR program identified through its AI-enabled discovered engine in clinical testing, with target engagement data expected in early January 2027ProQR’s expanded AI strategy is directly supporting the ongoing development programs; the Company expects up to 5 clinical data readouts over the next 12 months across 4 development programs LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 23, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transfo
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that the first participant has been dosed in the Phase 1 clinical trial of AX-0811 in healthy volunteers. AX-0811 is ProQR’s next-generation, AI-discovered investigational RNA editing oligonucleotide (EON) designed to modulate NTCP, with preclinical data demonstrating greater potency and a longer half-life compared with AX-0810. AX-0811 is being developed as a potential disease-modify
- PRProQR to Participate in Upcoming Investor Conferences in September 2026LEIDEN, Netherlands & CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a clinical-stage company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will participate in the following upcoming investor conferences: Wells Fargo 21st Annual Healthcare Conference – Boston, MA1x1s on Tuesday, September 82026 Cantor Global Healthcare Conference – New York, NYFireside chat at 11:30am ET and 1x1s on Wednesday, September 9 Additional details, including webcast information where applicable, will be accessible from t
- ANALYSTBofA Securities initiated coverage on ProQR Therapeutics with a new price targetBofA Securities initiated coverage of ProQR Therapeutics with a rating of Buy and set a new price target of $8.00
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Announces Second Quarter 2026 Operating and Financial ResultsFirst clinical validation of Axiomer™ RNA editing established through NTCP modulation with positive AX-0810 clinical target engagement data; full Phase 1 dataset to be presented at a medical or scientific conference later this yearMultiple clinical milestones, including initial AX-0811 Phase 1 data expected by year-end 2026, followed in H1 2027 by: biliary atresia IIT initiation and initial data, initial AX-0422 (IDUA) patient data in MPS I Hurler syndrome, and advancement of AX-2911 (PNPLA3) to the clinic Strengthened balance sheet through $59.2 million financing during the quarter; ended Q2 2026 with € 117.1 million cash and cash equivalents, supporting runway through mid-2028 LEIDEN, Net
- INSIDERChief Executive Officer De Boer Daniel Anton bought $353,960 worth of Ordinary Shares (200,000 units at $1.77), increasing direct ownership by 67% to 500,000 units (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form SCHEDULE 13G filed by ProQR Therapeutics N.V.SCHEDULE 13G - ProQR Therapeutics N.V. (0001612940) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ProQR Therapeutics N.V.SCHEDULE 13G/A - ProQR Therapeutics N.V. (0001612940) (Subject)
- INSIDERDirector Filius Bart bought $257,925 worth of Ordinary Shares (150,000 units at $1.72), increasing direct ownership by 100% to 300,000 units (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form EFFECT filed by ProQR Therapeutics N.V.EFFECT - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 424B5 filed by ProQR Therapeutics N.V.424B5 - ProQR Therapeutics N.V. (0001612940) (Filer)
- INSIDERChief Executive Officer De Boer Daniel Anton bought $261,000 worth of Ordinary Shares (150,000 units at $1.74), increasing direct ownership by 100% to 300,000 units (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERChief Executive Officer De Boer Daniel Anton bought $238,500 worth of Ordinary Shares (150,000 units at $1.59) (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form F-3 filed by ProQR Therapeutics N.V.F-3 - ProQR Therapeutics N.V. (0001612940) (Filer)
- INSIDERAmendment: SEC Form 4 filed by Director Hinsch Gylvin Lykke4/A - ProQR Therapeutics N.V. (0001612940) (Issuer)
- INSIDERDirector Filius Bart bought $231,000 worth of Ordinary Shares (150,000 units at $1.54) (SEC Form 4)4 - ProQR Therapeutics N.V. (0001612940) (Issuer)
- SECSEC Form 6-K filed by ProQR Therapeutics N.V.6-K - ProQR Therapeutics N.V. (0001612940) (Filer)
- SECSEC Form 424B5 filed by ProQR Therapeutics N.V.424B5 - ProQR Therapeutics N.V. (0001612940) (Filer)
- PRProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private PlacementLEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) ("ProQR"), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the "Offering") at an offering price of $1.81 per share (the "Offering Price"), for total gross proceeds of approximately $50.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by ProQR. Concurrently with the Offering, ProQR has entered into a
PRQR FAQ
11 questionsWhat does ProQR Therapeutics N.V. do?
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It is primarily developing sepofarsen that is in phase II/III illuminate trial for treating leber's congenital amaurosis 10 disease; QR-421a, which is in phase I/II stellar trial for usher syndrome type 2 and non-syndromic retinitis pigmentosa; QR-1123 that is in phase I/II aurora trial for the treatment of autosomal dominant retinitis pigmentosa; and QR-504a, which is in first clinical trial for the treatment of fuchs endothelial...What is the latest news on PRQR?
In the last 30 days Quantisnow tracked 2 wire items for PRQR: 2 SEC filings. The most recent was published on October 30, 2026.What is PRQR revenue?
ProQR Therapeutics N.V. (PRQR) reported €15.91M of revenue for fiscal 2025 (ended Dec 31, 2025). That is down 15.9% from the year before.Is PRQR profitable?
No. ProQR Therapeutics N.V. reported a net loss of €42.18M for fiscal 2025 (ended Dec 31, 2025).How much cash and debt does PRQR have?
ProQR Therapeutics N.V. reported €92.41M in cash and cash equivalents and €4.87M of debt on its most recent balance sheet in SEC filings.Where does PRQR stock trade?
ProQR Therapeutics N.V. (PRQR) is listed on NASDAQ.What sector and industry is PRQR in?
ProQR Therapeutics N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did ProQR Therapeutics N.V. go public?
ProQR Therapeutics N.V. (PRQR) completed its IPO in 2014.What are analysts saying about PRQR?
Across the last 8 analyst actions on ProQR Therapeutics N.V., there were 3 upgrades and 0 downgrades. The most recent action was from BofA Securities: Buy with a $8.00 price target on 2026-08-20.What companies are similar to PRQR?
Notable peers in the same industry include ABT (Abbott Laboratories), MRK (Merck & Company Inc.), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare PRQR side-by-side with any of them on Quantisnow.How can I track PRQR on Quantisnow?
Quantisnow aggregates ProQR Therapeutics N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PRQR to receive live email and push alerts on every new disclosure.